374 related articles for article (PubMed ID: 1570015)
1. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
3. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21.
Hattori S; Maekawa M; Nakamura S
Oncogene; 1992 Mar; 7(3):481-5. PubMed ID: 1549362
[TBL] [Abstract][Full Text] [Related]
4. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
Stang S; Bottorff D; Stone JC
Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of rasGAP and neurofibromatosis gene product activities.
Bollag G; McCormick F
Nature; 1991 Jun; 351(6327):576-9. PubMed ID: 1904555
[TBL] [Abstract][Full Text] [Related]
6. [Molecular genetics of neurofibromatosis type 1].
Suzuki H; Takahashi K; Shibahara S
Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
[TBL] [Abstract][Full Text] [Related]
7. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
[TBL] [Abstract][Full Text] [Related]
8. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
9. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
[TBL] [Abstract][Full Text] [Related]
10. Ras regulation. NF is enough of GAP.
Bollag G; McCormick F
Nature; 1992 Apr; 356(6371):663-4. PubMed ID: 1570011
[No Abstract] [Full Text] [Related]
11. Characterization of Ras effector mutant interactions with the NF1-GAP related domain.
Marshall MS; Hettich LA
Oncogene; 1993 Feb; 8(2):425-31. PubMed ID: 8426748
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Ras signaling pathway by GTPase-activating protein in PC12 cells.
Yao R; Cooper GM
Oncogene; 1995 Oct; 11(8):1607-14. PubMed ID: 7478585
[TBL] [Abstract][Full Text] [Related]
13. Suppression of c-ras transformation by GTPase-activating protein.
Zhang K; DeClue JE; Vass WC; Papageorge AG; McCormick F; Lowy DR
Nature; 1990 Aug; 346(6286):754-6. PubMed ID: 2201922
[TBL] [Abstract][Full Text] [Related]
14. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway.
Buchberg AM; Cleveland LS; Jenkins NA; Copeland NG
Nature; 1990 Sep; 347(6290):291-4. PubMed ID: 2169593
[TBL] [Abstract][Full Text] [Related]
15. Regulatory mechanisms for ras proteins.
Downward J
Bioessays; 1992 Mar; 14(3):177-84. PubMed ID: 1586371
[TBL] [Abstract][Full Text] [Related]
16. Interactions between p21ras proteins and their GTPase activating proteins.
Polakis P; McCormick F
Cancer Surv; 1992; 12():25-42. PubMed ID: 1386285
[TBL] [Abstract][Full Text] [Related]
17. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras.
Gutmann DH; Giordano MJ; Mahadeo DK; Lau N; Silbergeld D; Guha A
Oncogene; 1996 May; 12(10):2121-7. PubMed ID: 8668337
[TBL] [Abstract][Full Text] [Related]
18. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes.
Kim HA; Rosenbaum T; Marchionni MA; Ratner N; DeClue JE
Oncogene; 1995 Jul; 11(2):325-35. PubMed ID: 7624147
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
20. [NF1 (neurofibromatosis type 1)].
Maruta H; Nur-e-Kamal
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1422-6. PubMed ID: 9309135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
